Form 4: Merit Medical CEO Sells 20,000 Shares Under Pre-Arranged Trading Plan

Merit Medical Systems Inc.'s President and CEO, Fred P. Lampropoulos, reported the sale of 20,000 shares of common stock for approximately $1.93 million, executed under a Rule 10b5-1 trading plan.

Summary

• Fred P. Lampropoulos, President and CEO of Merit Medical Systems Inc. (MMSI), reported the sale of 20,000 shares of common stock.
• The transaction occurred on May 27, 2025, at a weighted average price of $96.54 per share, totaling approximately $1,930,800.
• The sale was conducted under a Rule 10b5-1(c) pre-arranged trading plan, indicating it was scheduled in advance.
• Following the sale, Mr. Lampropoulos directly beneficially owns 1,066,028 shares of common stock.
• He also holds indirect beneficial ownership of 7,734.258 shares through his spouse, 97,798 shares through a 401(k) Plan, and 90 shares through his spouse as custodian for a child.
• Additionally, Mr. Lampropoulos holds various non-qualified stock options, including 159,151 options at $55.73, 100,334 options at $37.71, 58,083 options at $56.25, and 54,302 options at $70.58, all directly owned.
• An additional 2,000 non-qualified stock options at $55.73 are held indirectly by his spouse, for which he expressly disclaims beneficial ownership.

Sentiment

Score: 4

Explanation: The sale of shares by the CEO, while a reduction in direct holdings, was conducted under a pre-arranged Rule 10b5-1 plan, which suggests it was not based on new, adverse information. The CEO retains a substantial direct and indirect stake, including significant stock options, mitigating significant negative sentiment.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, which indicates it was pre-scheduled and not based on immediate, non-public information, mitigating concerns about opportunistic insider selling.
• Despite the sale, the CEO retains a substantial direct beneficial ownership of 1,066,028 shares, demonstrating continued alignment with shareholder interests.
• The CEO also holds a significant number of in-the-money stock options, further aligning his interests with the company's stock performance.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.
• The sale of 20,000 shares represents a reduction in the CEO's direct holdings, though it is a small percentage of his total beneficial ownership.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends for the medical device sector in which Merit Medical Systems operates. Such filings are routine disclosures of changes in beneficial ownership by company insiders.

Stakeholder Impact

• Shareholders: The sale by the CEO could be interpreted by some shareholders as a slight negative signal, though the Rule 10b5-1 plan mitigates this. The CEO's continued significant ownership stake maintains alignment.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

Keywords

Merit Medical Systems Inc., MMSI, SEC Form 4, Insider Trading, Stock Sale, CEO, Fred P. Lampropoulos, Rule 10b5-1, Common Stock, Beneficial Ownership